Inclusion criteria
|
(1)The patient's diagnostic criteria were in line with the above-mentioned western diagnostic criteria and traditional Chinese diagnostic criteria;
(2)The patients were between 40 and 75 years old;
(3)Patients who have not received systematic treatment recently have not taken painkillers
(4)Subjects with limited joint flexion and extension activities due to traction pain at the back of the knee joint with or without other meridian sinew types
(5)The subjects voluntarily participated in the study, signed the informed consent, and were willing to cooperate in filling in relevant data and receiving follow-up visits.
|
Exclusion criteria:
|
(1)Patients with Kellgren-Lawrence grade IV radiographic manifestations, significant narrowing of joint space and subchondral sclerosis;
(2)Subjects who had received arthroscopic surgery or open surgery for the previously diseased knee;
(3)Patients with other rheumatic immune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, ankylosing spondylitis, etc
(4)Patients with secondary knee OA, such as acute and chronic knee infection, tumor, tuberculosis, hematological and traumatic diseases
(5)Patients with severe knee deformity, varus > 10°, varus > 20°, and complete loss of joint space are not suitable for conservative treatment
(6)Patients with serious primary cardiovascular disease, lung disease, metabolic disease, endocrine disease, abnormal coagulation mechanism or other serious diseases affecting survival
(7)In the last 3 months, the patient received acetaminophen, chondrotrophic drugs, articular cavity injection drugs and other related treatments
(8)Patients who cannot cooperate with MRI examination and have contraindications for MRI examination;
(9)Patients with contraindications of extracorporeal shock wave therapy;
(10)Pregnant or lactating women;
(11)The patient is suspected or has a history of alcohol or drug abuse, or has other medical conditions that, in the judgment of the investigator, may reduce the possibility of enrollment or complicate enrollment, or may cause loss of follow-up;
(12) Patients with serious adverse reactions and contraindications of celecoxib capsules;
(13) Other circumstances in which the researcher considers that the experiment cannot be successfully completed.
If subjects meet any of the above criteria, they are excluded cases.
|